Another Chinese Synthetic Biology Company Receives Investment
- Chaileedo Press
- Dec 6, 2022
- 2 min read
GsynBioT will develop new and efficient cosmetic products of different categories by studying the functional mechanisms and drug-forming properties of natural compounds to meet the needs of different levels of human health.
GsynBioT (Suzhou) Biological Technology Company Ltd. (hereinafter referred to as GsynBioT) announced the completion of a Pre Series A financing round of tens of millions of RMB, led by Addor Capital, followed by CAS Angel Fund and Jianpu Capital, with T9 Capital as the exclusive financial advisor.
It is reported that this round of financing transaction was completed in early October this year, and the funds raised will be used for the construction of a GMP-compliant natural product biomanufacturing demonstration line and product application research and development.
GsynBioT Zhao Guopin, Chairman of GsynBioT, said that GsynBioT is doing two types of transformation: firstly, to provide a large number of high quality and reasonably priced natural compound monomers to the market. On the other hand, it hopes to work with scientists or companies in drug, health care and cosmetic R&D institutions to conduct in-depth research on the functional mechanisms and drug-forming properties of ginsenoside monomers and other natural compounds. It aims to develop new and efficient products in different categories for different levels of human health needs.
The successful completion of the Pre-A round of financing will help GsynBioT to continuously and efficiently launch new products that are beneficial to human health, and help synthetic biology to be "useful".
Ginsenoside, as the representative product of GsynBioT, has great commercial opportunities in the markets of pharmaceuticals, health care products, functional foods and cosmetics in the future. At present, through the biosynthesis preparation technology of ab initio synthesis, GsynBioT can achieve high yield, high purity and low-cost production of various monomeric components of ginsenoside, which has significant advantages in the process of occupying the market.
At present, GsynBioT has formed a complete biotechnology platform for pathway analysis, design, reconstruction and targeted heterologous synthesis of natural compounds. In the future, it will combine the biological components and database built by the team in the early stage. It will build a global leading technology platform for the synthetic biology of natural products by introducing AI technology to create the rational design of biological components and automated casting technology of cell factories.
At the same time, GsynBioT has also made a series of short, medium and long-term deployments in the production and sales of raw materials of natural compounds such as ginsenoside monomers and their product development in cosmetics, health care products and pharmaceuticals. In the short term, it will produce and sell raw materials for cosmetic products. In the medium term, it will develop precise health food products for the "cure for the untreated" as claimed by Chinese medicine or "sub-health" as referred to by modern medicine.
Comments